Stephen E Jones1, Rufus Collea2, Devchand Paul3, Scot Sedlacek3, Anne M Favret4, Ira Gore5, Deborah L Lindquist6, Frankie Ann Holmes7, Mary Ann K Allison8, Barry D Brooks9, Raul M Portillo10, Svetislava J Vukelja11, Michael S Steinberg12, Christopher Stokoe13, Maria W Crockett14, Yunfei Wang14, Lina Asmar14, Nicholas J Robert4, Joyce O'Shaughnessy15. 1. US Oncology Research, McKesson Specialty Health, The Woodlands, TX, USA. Electronic address: steve.jones@usoncology.com. 2. US Oncology Research, McKesson Specialty Health, The Woodlands, TX, USA; New York Oncology Hematology, Albany, NY, USA. 3. US Oncology Research, McKesson Specialty Health, The Woodlands, TX, USA; Rocky Mountain Cancer, Denver, CO, USA. 4. US Oncology Research, McKesson Specialty Health, The Woodlands, TX, USA; Virginia Cancer Specialists, Fairfax, VA, USA. 5. US Oncology Research, McKesson Specialty Health, The Woodlands, TX, USA; Alabama Oncology, Birmingham, AL, USA. 6. US Oncology Research, McKesson Specialty Health, The Woodlands, TX, USA; Arizona Oncology, Sedona, AZ, USA. 7. US Oncology Research, McKesson Specialty Health, The Woodlands, TX, USA; Texas Oncology, Houston Memorial City, Houston, TX, USA. 8. US Oncology Research, McKesson Specialty Health, The Woodlands, TX, USA; Comprehensive Cancer Centers of Nevada, Henderson, NV, USA. 9. US Oncology Research, McKesson Specialty Health, The Woodlands, TX, USA; Texas Oncology, Medical City Dallas, Dallas, TX, USA. 10. US Oncology Research, McKesson Specialty Health, The Woodlands, TX, USA; Texas Oncology, El Paso West, El Paso, TX, USA. 11. US Oncology Research, McKesson Specialty Health, The Woodlands, TX, USA; Texas Oncology-Tyler, Tyler, TX, USA. 12. US Oncology Research, McKesson Specialty Health, The Woodlands, TX, USA; Virginia Oncology Associates, Virginia Beach, VA, USA. 13. US Oncology Research, McKesson Specialty Health, The Woodlands, TX, USA; Texas Oncology, Plano East, Plano, TX, USA. 14. US Oncology Research, McKesson Specialty Health, The Woodlands, TX, USA. 15. US Oncology Research, McKesson Specialty Health, The Woodlands, TX, USA; Texas Oncology, Baylor-Sammons Cancer Center, Dallas, TX, USA.
Abstract
BACKGROUND: Previous results suggest that docetaxel plus cyclophosphamide improves disease-free survival (DFS) and overall survival compared with doxorubicin plus cyclophosphamide in early stage breast cancer. We assessed the addition of 1 year of trastuzumab to a non-anthracycline regimen, docetaxel plus cyclophosphamide, in patients with HER2-amplified early stage breast cancer and examined whether this regimen was equally effective in patients with TOP2A-amplified and TOP2A-non-amplified disease. METHODS: This was an open-label, single-group, phase 2 study. Eligible patients were aged 18-75 years; had Eastern Cooperative Oncology Group performance status of 1 or less; HER2-amplified early stage breast cancer; operable, histologically confirmed, invasive carcinoma of the breast; adequate tumour specimen available for FISH analysis of TOP2A status; and adequate haematological, renal, hepatic, and cardiac function. Patients received four 21-day cycles of intravenous docetaxel 75 mg/m(2), plus intravenous cyclophosphamide 600 mg/m(2), plus intravenous trastuzumab 4 mg/kg (loading dose) on day 1 and 2 mg/kg on days 1, 8, and 15 during chemotherapy, followed by trastuzumab 6 mg/kg every three weeks for the remainder of 1 year. The primary endpoint was 2-year DFS in TOP2A-amplified and TOP2A-non-amplified patients; the primary analysis was done by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00493649. FINDINGS: 493 patients were enrolled between June 15, 2007, and Aug 5, 2009. After a median follow-up of 36·1 months (IQR 35·5-36·7), 2-year DFS was 97·8% (95% CI 94·2-99·2) and 2-year overall survival was 99·5% (95% CI 96·2-99·9) for the 190 patients with TOP2A-amplified disease; 2-year DFS was 97·9% (95% CI 94·9-99·1) and 2-year overall survival was 98·8% (95% CI 96·2-99·6) for the 248 patients with TOP2A-non-amplified disease; 55 patients were not assessable for TOP2A status. In the 486 patients who received at least one dose of study drug, the most common adverse events of any grade were fatigue (284 patients, 58·4%), neutropenia (250, 51·4%), and nausea (217, 44·7%). The most common grade 3-4 toxic effects were neutropenia (229, 47·1%), febrile neutropenia (30, 6·2%), fatigue (21, 4·3%), and diarrhoea (16, 3·3%). Cardiac dysfunction occurred in 29 (6·0%) patients (12 [2·5%] grade 1, 15 [3·1%] grade 2, and two [0·4%] grade 3). 23 patients had at least one study-related serious adverse event. 16 patients stopped trastuzumab because of cardiac dysfunction. INTERPRETATION: A short, four-cycle regimen of docetaxel and cyclophosphamide combined with trastuzumab could be an option for adjuvant treatment of women with lower risk HER2-amplified early breast cancer, irrespective of TOP2A status. FUNDING: Sanofi.
BACKGROUND: Previous results suggest that docetaxel plus cyclophosphamide improves disease-free survival (DFS) and overall survival compared with doxorubicin plus cyclophosphamide in early stage breast cancer. We assessed the addition of 1 year of trastuzumab to a non-anthracycline regimen, docetaxel plus cyclophosphamide, in patients with HER2-amplified early stage breast cancer and examined whether this regimen was equally effective in patients with TOP2A-amplified and TOP2A-non-amplified disease. METHODS: This was an open-label, single-group, phase 2 study. Eligible patients were aged 18-75 years; had Eastern Cooperative Oncology Group performance status of 1 or less; HER2-amplified early stage breast cancer; operable, histologically confirmed, invasive carcinoma of the breast; adequate tumour specimen available for FISH analysis of TOP2A status; and adequate haematological, renal, hepatic, and cardiac function. Patients received four 21-day cycles of intravenous docetaxel 75 mg/m(2), plus intravenous cyclophosphamide 600 mg/m(2), plus intravenous trastuzumab 4 mg/kg (loading dose) on day 1 and 2 mg/kg on days 1, 8, and 15 during chemotherapy, followed by trastuzumab 6 mg/kg every three weeks for the remainder of 1 year. The primary endpoint was 2-year DFS in TOP2A-amplified and TOP2A-non-amplified patients; the primary analysis was done by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00493649. FINDINGS: 493 patients were enrolled between June 15, 2007, and Aug 5, 2009. After a median follow-up of 36·1 months (IQR 35·5-36·7), 2-year DFS was 97·8% (95% CI 94·2-99·2) and 2-year overall survival was 99·5% (95% CI 96·2-99·9) for the 190 patients with TOP2A-amplified disease; 2-year DFS was 97·9% (95% CI 94·9-99·1) and 2-year overall survival was 98·8% (95% CI 96·2-99·6) for the 248 patients with TOP2A-non-amplified disease; 55 patients were not assessable for TOP2A status. In the 486 patients who received at least one dose of study drug, the most common adverse events of any grade were fatigue (284 patients, 58·4%), neutropenia (250, 51·4%), and nausea (217, 44·7%). The most common grade 3-4 toxic effects were neutropenia (229, 47·1%), febrile neutropenia (30, 6·2%), fatigue (21, 4·3%), and diarrhoea (16, 3·3%). Cardiac dysfunction occurred in 29 (6·0%) patients (12 [2·5%] grade 1, 15 [3·1%] grade 2, and two [0·4%] grade 3). 23 patients had at least one study-related serious adverse event. 16 patients stopped trastuzumab because of cardiac dysfunction. INTERPRETATION: A short, four-cycle regimen of docetaxel and cyclophosphamide combined with trastuzumab could be an option for adjuvant treatment of women with lower risk HER2-amplified early breast cancer, irrespective of TOP2A status. FUNDING: Sanofi.
Authors: Chau T Dang; Anthony F Yu; Lee W Jones; Jennifer Liu; Richard M Steingart; Daniel F Argolo; Larry Norton; Clifford A Hudis Journal: J Clin Oncol Date: 2016-02-01 Impact factor: 44.544
Authors: Anthony F Yu; Roy B Mukku; Shivani Verma; Jennifer E Liu; Kevin C Oeffinger; Richard M Steingart; Clifford A Hudis; Chau T Dang Journal: Breast Cancer Res Treat Date: 2017-07-14 Impact factor: 4.872
Authors: Tessa G Steenbruggen; Mette S van Ramshorst; Marleen Kok; Sabine C Linn; Carolien H Smorenburg; Gabe S Sonke Journal: Drugs Date: 2017-08 Impact factor: 9.546
Authors: Helena Earl; Louise Hiller; Anne-Laure Vallier; Shrushma Loi; Karen McAdam; Luke Hughes-Davies; Daniel Rea; Donna Howe; Kerry Raynes; Helen B Higgins; Maggie Wilcox; Chris Plummer; Betania Mahler-Araujo; Elena Provenzano; Anita Chhabra; Sophie Gasson; Claire Balmer; Jean E Abraham; Carlos Caldas; Peter Hall; Bethany Shinkins; Christopher McCabe; Claire Hulme; David Miles; Andrew M Wardley; David A Cameron; Janet A Dunn Journal: Health Technol Assess Date: 2020-08 Impact factor: 4.014
Authors: Stefania Mantarro; Marta Rossi; Martina Bonifazi; Roberto D'Amico; Corrado Blandizzi; Carlo La Vecchia; Eva Negri; Lorenzo Moja Journal: Intern Emerg Med Date: 2015-12-28 Impact factor: 3.397
Authors: Chau Dang; Hao Guo; Julie Najita; Denise Yardley; Kelly Marcom; Kathy Albain; Hope Rugo; Kathy Miller; Matthew Ellis; Iuliana Shapira; Antonio C Wolff; Lisa A Carey; Beverly Moy; John Groarke; Javid Moslehi; Ian Krop; Harold J Burstein; Clifford Hudis; Eric P Winer; Sara M Tolaney Journal: JAMA Oncol Date: 2016-01 Impact factor: 31.777
Authors: Somaira Nowsheen; Paul V Viscuse; Ciara C O'Sullivan; Nicole P Sandhu; Tufia C Haddad; Anne Blaes; Jennifer Klemp; Lara Nhola; Joerg Herrmann; Kathryn J Ruddy Journal: Curr Breast Cancer Rep Date: 2017-07-14